Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
432 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Fallopian Tube Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Fallopian Tube Cancer - Pipeline Review, H1 2015’, provides an overview of the Fallopian Tube Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fallopian Tube Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fallopian Tube Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fallopian Tube Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fallopian Tube Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fallopian Tube Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 9 Global Markets Direct Report Coverage 9 Fallopian Tube Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Fallopian Tube Cancer - Overview 11 Pipeline Products for Fallopian Tube Cancer - Comparative Analysis 12 Fallopian Tube Cancer - Therapeutics under Development by Companies 13 Fallopian Tube Cancer - Therapeutics under Investigation by Universities/Institutes 18 Fallopian Tube Cancer - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Fallopian Tube Cancer - Products under Development by Companies 22 Fallopian Tube Cancer - Products under Investigation by Universities/Institutes 27 Fallopian Tube Cancer - Companies Involved in Therapeutics Development 28 AbbVie Inc. 28 Acceleron Pharma, Inc. 29 Adaptimmune Limited 30 Amgen Inc. 31 Array BioPharma Inc. 32 Astex Pharmaceuticals, Inc. 33 AstraZeneca PLC 34 Bayer AG 35 BioMarin Pharmaceutical Inc. 36 Bionomics Limited 37 Boehringer Ingelheim GmbH 38 Celldex Therapeutics, Inc. 39 Celsion Corporation 40 Cerulean Pharma, Inc. 41 Clovis Oncology, Inc. 42 Corcept Therapeutics Incorporated 43 CTI BioPharma Corp. 44 Curis, Inc. 45 Eli Lilly and Company 46 Exelixis, Inc. 47 F. Hoffmann-La Roche Ltd. 48 Galena Biopharma, Inc. 49 Genentech, Inc. 50 GlaxoSmithKline plc 51 Glycotope GmbH 52 Gradalis Inc. 53 ImmunoGen, Inc. 54 Immunotope, Inc. 55 Immunovaccine, Inc. 56 Johnson & Johnson 57 Karyopharm Therapeutics, Inc. 58 Lee's Pharmaceutical Holdings Limited 59 MabVax Therapeutics Holdings, Inc. 60 MedImmune, LLC 61 Merck & Co., Inc. 62 Merrimack Pharmaceuticals, Inc. 63 Millennium Pharmaceuticals, Inc. 64 NeoStem, Inc. 65 Novartis AG 66 Oasmia Pharmaceutical AB 67 OBI Pharma, Inc. 68 Oncolytics Biotech Inc. 69 OncoMed Pharmaceuticals, Inc. 70 Onxeo SA 71 Oxford BioMedica plc 72 OXiGENE, Inc. 73 Pharma Mar, S.A. 74 Pharmacyclics, Inc. 75 PsiOxus Therapeutics, Ltd. 76 Recepta Biopharma S.A. 77 Sanofi Pasteur SA 78 Sotio a.s. 79 Synta Pharmaceuticals Corp. 80 TapImmune Inc. 81 Tesaro, Inc. 82 TetraLogic Pharmaceuticals 83 TRACON Pharmaceuticals, Inc. 84 VentiRx Pharmaceuticals, Inc. 85 Fallopian Tube Cancer - Therapeutics Assessment 86 Assessment by Monotherapy Products 86 Assessment by Target 87 Assessment by Mechanism of Action 91 Assessment by Route of Administration 94 Assessment by Molecule Type 96 Drug Profiles 98 abexinostat hydrochloride - Drug Profile 98 abiraterone acetate - Drug Profile 100 ABT-767 - Drug Profile 103 alisertib - Drug Profile 104 anetumab ravtansine - Drug Profile 108 AZD-1775 - Drug Profile 110 AZD-2014 - Drug Profile 112 AZD-5363 - Drug Profile 114 belinostat - Drug Profile 116 bevacizumab - Drug Profile 119 binimetinib - Drug Profile 124 birinapant - Drug Profile 128 BNC-105P - Drug Profile 131 cabozantinib s-malate - Drug Profile 133 Cancer Stem Cell Therapy - Drug Profile 136 CDX-1401 - Drug Profile 137 Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology - Drug Profile 139 Cell Therapy to Target WT1 for Cancer - Drug Profile 141 CRLX-101 - Drug Profile 142 CUDC-427 - Drug Profile 144 dalantercept - Drug Profile 145 DCVAC/OvCa - Drug Profile 147 demcizumab - Drug Profile 148 Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer - Drug Profile 152 DMUC-4064A - Drug Profile 153 DPX-Survivac - Drug Profile 154 EGEN-001 - Drug Profile 157 elesclomol - Drug Profile 159 enadenotucirev - Drug Profile 161 erismodegib - Drug Profile 163 fosbretabulin tromethamine - Drug Profile 166 GALE-301 - Drug Profile 170 ganetespib - Drug Profile 172 gimatecan - Drug Profile 176 guadecitabine - Drug Profile 178 IMGN-853 - Drug Profile 181 IMT-1012 - Drug Profile 182 ipafricept - Drug Profile 183 LCL-161 - Drug Profile 185 lifastuzumab vedotin - Drug Profile 187 LY-2606368 - Drug Profile 189 mifepristone - Drug Profile 190 MK-2206 - Drug Profile 193 motolimod - Drug Profile 196 nintedanib - Drug Profile 198 niraparib - Drug Profile 202 NSC-748933 - Drug Profile 204 OBI-822/821 - Drug Profile 205 olaratumab - Drug Profile 207 paclitaxel - Drug Profile 209 paclitaxel poliglumex - Drug Profile 211 PankoMab-GEX - Drug Profile 215 pazopanib hydrochloride - Drug Profile 216 pelareorep - Drug Profile 221 ralimetinib mesylate - Drug Profile 226 ramucirumab - Drug Profile 227 RebmAb-100 - Drug Profile 232 regorafenib - Drug Profile 234 rucaparib phosphate - Drug Profile 237 selinexor - Drug Profile 240 seribantumab - Drug Profile 244 SG-2000 - Drug Profile 247 talazoparib - Drug Profile 249 TPIV-200 - Drug Profile 252 trabectedin - Drug Profile 254 TRC-105 - Drug Profile 258 trebananib - Drug Profile 260 TroVax - Drug Profile 263 Vaccine for cancer - Drug Profile 266 Vaccine for Oncology - Drug Profile 268 varlilumab - Drug Profile 269 vCP-2292 - Drug Profile 271 X-82 - Drug Profile 273 Fallopian Tube Cancer - Recent Pipeline Updates 275 Fallopian Tube Cancer - Dormant Projects 417 Fallopian Tube Cancer - Discontinued Products 419 Fallopian Tube Cancer - Product Development Milestones 420 Featured News & Press Releases 420 Appendix 426 Methodology 426 Coverage 426 Secondary Research 426 Primary Research 426 Expert Panel Validation 426 Contact Us 426 Disclaimer 427
List of Tables Number of Products under Development for Fallopian Tube Cancer, H1 2015 16 Number of Products under Development for Fallopian Tube Cancer - Comparative Analysis, H1 2015 17 Number of Products under Development by Companies, H1 2015 19 Number of Products under Development by Companies, H1 2015 (Contd..1) 20 Number of Products under Development by Companies, H1 2015 (Contd..2) 21 Number of Products under Development by Companies, H1 2015 (Contd..3) 22 Number of Products under Investigation by Universities/Institutes, H1 2015 23 Comparative Analysis by Late Stage Development, H1 2015 24 Comparative Analysis by Clinical Stage Development, H1 2015 25 Comparative Analysis by Early Stage Development, H1 2015 26 Products under Development by Companies, H1 2015 27 Products under Development by Companies, H1 2015 (Contd..1) 28 Products under Development by Companies, H1 2015 (Contd..2) 29 Products under Development by Companies, H1 2015 (Contd..3) 30 Products under Development by Companies, H1 2015 (Contd..4) 31 Products under Investigation by Universities/Institutes, H1 2015 32 Fallopian Tube Cancer - Pipeline by AbbVie Inc., H1 2015 33 Fallopian Tube Cancer - Pipeline by Acceleron Pharma, Inc., H1 2015 34 Fallopian Tube Cancer - Pipeline by Adaptimmune Limited, H1 2015 35 Fallopian Tube Cancer - Pipeline by Amgen Inc., H1 2015 36 Fallopian Tube Cancer - Pipeline by Array BioPharma Inc., H1 2015 37 Fallopian Tube Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 38 Fallopian Tube Cancer - Pipeline by AstraZeneca PLC, H1 2015 39 Fallopian Tube Cancer - Pipeline by Bayer AG, H1 2015 40 Fallopian Tube Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 41 Fallopian Tube Cancer - Pipeline by Bionomics Limited, H1 2015 42 Fallopian Tube Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 43 Fallopian Tube Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 44 Fallopian Tube Cancer - Pipeline by Celsion Corporation, H1 2015 45 Fallopian Tube Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 46 Fallopian Tube Cancer - Pipeline by Clovis Oncology, Inc., H1 2015 47 Fallopian Tube Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015 48 Fallopian Tube Cancer - Pipeline by CTI BioPharma Corp., H1 2015 49 Fallopian Tube Cancer - Pipeline by Curis, Inc., H1 2015 50 Fallopian Tube Cancer - Pipeline by Eli Lilly and Company, H1 2015 51 Fallopian Tube Cancer - Pipeline by Exelixis, Inc., H1 2015 52 Fallopian Tube Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 53 Fallopian Tube Cancer - Pipeline by Galena Biopharma, Inc., H1 2015 54 Fallopian Tube Cancer - Pipeline by Genentech, Inc., H1 2015 55 Fallopian Tube Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 56 Fallopian Tube Cancer - Pipeline by Glycotope GmbH, H1 2015 57 Fallopian Tube Cancer - Pipeline by Gradalis Inc., H1 2015 58 Fallopian Tube Cancer - Pipeline by ImmunoGen, Inc., H1 2015 59 Fallopian Tube Cancer - Pipeline by Immunotope, Inc., H1 2015 60 Fallopian Tube Cancer - Pipeline by Immunovaccine, Inc., H1 2015 61 Fallopian Tube Cancer - Pipeline by Johnson & Johnson, H1 2015 62 Fallopian Tube Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 63 Fallopian Tube Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 64 Fallopian Tube Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 65 Fallopian Tube Cancer - Pipeline by MedImmune, LLC, H1 2015 66 Fallopian Tube Cancer - Pipeline by Merck & Co., Inc., H1 2015 67 Fallopian Tube Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 68 Fallopian Tube Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 69 Fallopian Tube Cancer - Pipeline by NeoStem, Inc., H1 2015 70 Fallopian Tube Cancer - Pipeline by Novartis AG, H1 2015 71 Fallopian Tube Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015 72 Fallopian Tube Cancer - Pipeline by OBI Pharma, Inc., H1 2015 73 Fallopian Tube Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 74 Fallopian Tube Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 75 Fallopian Tube Cancer - Pipeline by Onxeo SA, H1 2015 76 Fallopian Tube Cancer - Pipeline by Oxford BioMedica plc, H1 2015 77 Fallopian Tube Cancer - Pipeline by OXiGENE, Inc., H1 2015 78 Fallopian Tube Cancer - Pipeline by Pharma Mar, S.A., H1 2015 79 Fallopian Tube Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 80 Fallopian Tube Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 81 Fallopian Tube Cancer - Pipeline by Recepta Biopharma S.A., H1 2015 82 Fallopian Tube Cancer - Pipeline by Sanofi Pasteur SA, H1 2015 83 Fallopian Tube Cancer - Pipeline by Sotio a.s., H1 2015 84 Fallopian Tube Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 85 Fallopian Tube Cancer - Pipeline by TapImmune Inc., H1 2015 86 Fallopian Tube Cancer - Pipeline by Tesaro, Inc., H1 2015 87 Fallopian Tube Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2015 88 Fallopian Tube Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 89 Fallopian Tube Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 90 Assessment by Monotherapy Products, H1 2015 91 Number of Products by Stage and Target, H1 2015 93 Number of Products by Stage and Mechanism of Action, H1 2015 97 Number of Products by Stage and Route of Administration, H1 2015 100 Number of Products by Stage and Molecule Type, H1 2015 102 Fallopian Tube Cancer Therapeutics - Recent Pipeline Updates, H1 2015 280 Fallopian Tube Cancer - Dormant Projects, H1 2015 422 Fallopian Tube Cancer - Dormant Projects (Contd..1), H1 2015 423 Fallopian Tube Cancer - Discontinued Products, H1 2015 424
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
